Document Detail


The jaundiced newborn. Understanding and managing transitional hyperbilirubinemia.
MedLine Citation:
PMID:  12244276     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Neonatal jaundice is one of the most common conditions diagnosed by the pediatrician. This normally benign transitional phenomenon is a dynamic balance between the production and elimination of bilirubin. These processes can be exacerbated by a number of pathophysiologic conditions, which cause either an increase in bilirubin production rates, such as hemolysis, or a decrease in bilirubin elimination rates, such as bilirubin conjugation defects. The most dangerous circumstance for an infant is the combination of increased bilirubin production with impaired elimination. These infants are at considerable risk for developing excessive and potentially dangerous hyperbilirubinemia and subsequent kernicterus. Therefore, the importance of early recognition of the imbalance is paramount. In this review, we will discuss the various risk factors associated with hyperbilirubinemia and describe strategies for the diagnosis and management of transitional hyperbilirubinemia.
Authors:
D K Stevenson; R J Wong; S R Hintz; H J Vreman
Related Documents :
86296 - Lipoprotein-x and other tests in the diagnosis of obstructive jaundice in the infant.
2516696 - Carboxyhemoglobin measurements in the diagnosis of abo hemolytic disease.
12244276 - The jaundiced newborn. understanding and managing transitional hyperbilirubinemia.
11948386 - Effect of position changing on bilirubin levels during phototherapy.
8374216 - Changing survival and impairment rates at 18-24 months in outborn very low-birth-weight...
20670306 - Predictive value of the 1-min apgar score for survival at 23-26 weeks gestational age.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Minerva pediatrica     Volume:  54     ISSN:  0026-4946     ISO Abbreviation:  Minerva Pediatr.     Publication Date:  2002 Oct 
Date Detail:
Created Date:  2002-09-23     Completed Date:  2003-01-08     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0400740     Medline TA:  Minerva Pediatr     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  373-82     Citation Subset:  IM    
Affiliation:
Division of Neonatal, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA. dstevenson@stanford.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Bilirubin / biosynthesis
Forecasting
Heme / metabolism
Humans
Infant, Newborn
Jaundice, Neonatal / therapy*
Kernicterus / diagnosis
Time Factors
Grant Support
ID/Acronym/Agency:
HL58013/HL/NHLBI NIH HHS; HL68703/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
14875-96-8/Heme; 635-65-4/Bilirubin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Growth hormone treatment in children with cystic fibrosis.
Next Document:  Foetal and neonatal thyroid disorders.